Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Ken Song, CEO of San Diego-based Candid Therapeut…
The Long Run with Luke Timmerman · Timmerman Report
March 3, 20261h 5m
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.